<DOC>
	<DOC>NCT01176097</DOC>
	<brief_summary>The purpose of this study is to investigate the safety and tolerability of AZD5658 following ascending single oral doses in Type 2 Diabetics. It will also estimate the maximum tolerated dose.</brief_summary>
	<brief_title>To Assess Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Effect of Fasting After Single Oral Doses of AZD5658 in Type 2 Diabetes</brief_title>
	<detailed_description>This is a randomized, single-blind, placebo-controlled, single-center, phase 1 study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and the effect of fasting after single ascending oral doses of AZD5658 in type 2 diabetes mellitus patients.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Patients must be of nonchildbearing potential. Body mass index between greater than or equal to 19 and less than or equal to 40 kg/m2 Patients with confirmed Type 2 Diabetes diagnosis for at least 1 year and treated with Metformin Clinically significant illness or clinically relevant trauma within 2 weeks before the first administration of the IP Participation in another clinical study during the last 30 days prior to enrollment Significant cardiovascular event within the last 6 months prior to enrollment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>First in man study evaluating AZD5658 in Type 2 Diabetics.</keyword>
	<keyword>Effect of fasting</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
</DOC>